Immunogenicity, Reactogenicity and Safety of Two Formulations of GSK Biologicals' Meningococcal ACWY Conjugate Vaccine (GSK3536820A and Menveo) in Healthy Adults 18 to 40 Years of Age
Phase of Trial: Phase II
Latest Information Update: 05 Dec 2019
Price : $35 *
At a glance
- Drugs Meningococcal vaccine groups A C Y W-135 conjugate (Primary)
- Indications Bacterial meningitis; Meningococcal group A infections; Meningococcal group C infections; Meningococcal group W-135 infections; Meningococcal group Y infections; Meningococcal infections; Meningococcal meningitis
- Focus Pharmacodynamics
- Acronyms MENACWY CONJ-032_V59_71
- Sponsors GlaxoSmithKline
- 18 Sep 2019 Status changed from active, no longer recruiting to completed.
- 05 Feb 2019 Status changed from recruiting to active, no longer recruiting.
- 17 Sep 2018 Status changed from not yet recruiting to recruiting.